MiR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein

Experimental Cell Research

Volumn 319, Issue 8, 2013, Pages 1094-1101

  Li, Yajuan ^a   Wang, Haixia ^a   Tao, Kun ^a   Xiao, Qing ^a   Huang, Zhenglan ^a   Zhong, Liang ^a   Cao, Weixi ^a   Wen, Jianping ^b   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Apoptosis; BCR ABL1; Chronic myelogenous leukemia; MiR 29b; Proliferation

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; LUCIFERASE; MICRORNA 29B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

EID: 84876082504     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.02.002     Document Type: Article

References (24)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005, 5:172-183.
2. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
3. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002, 346:645-652.
4. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
5. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
6. Machova Polakova K., Lopotova T., Klamova H., Burda P., Trneny M., Stopka T., Moravcova J. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol. Cancer 2011, 10:41.
7. Bueno M.J., de Castro I.Perez, de Cedron M.Gomez, Santos J., Calin G.A., Cigudosa J.C., Croce C.M., Fernandez-Piqueras J., Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496-506.
8. Lopotova T., Zackova M., Klamova H., Moravcova J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?. Leuk. Res. 2011, 35:974-977.
9. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., Havelange V., Volinia S., Blum W., Rush L.J., Perrotti D., Andreeff M., Bloomfield C.D., Byrd J.C., Chan K., Wu L.C., Croce C.M., Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
10. Santanam U., Zanesi N., Efanov A., Costinean S., Palamarchuk A., Hagan J.P., Volinia S., Alder H., Rassenti L., Kipps T., Croce C.M., Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12210-12215.
11. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5874-5878.
12. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., Volinia S., Guler G., Morrison C.D., Chan K.K., Marcucci G., Calin G.A., Huebner K., Croce C.M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15805-15810.
13. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
14. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
15. Park S.Y., Lee J.H., Ha M., Nam J.W., Kim V.N. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol. 2009, 16:23-29.
16. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., Zanesi N., Kornblau S.M., Marcucci G., Calin G.A., Andreeff M., Croce C.M. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
17. Clark S.S., McLaughlin J., Crist W.M., Champlin R., Witte O.N. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987, 235:85-88.
18. Wang V., Wu W. MicroRNA-based therapeutics for cancer. BioDrugs 2009, 23:15-23.
19. Zhao J.J., Lin J., Lwin T., Yang H., Guo J., Kong W., Dessureault S., Moscinski L.C., Rezania D., Dalton W.S., Sotomayor E., Tao J., Cheng J.Q. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.
20. Garzon R., Volinia S., Liu C.G., Fernandez-Cymering C., Palumbo T., Pichiorri F., Fabbri M., Coombes K., Alder H., Nakamura T., Flomenberg N., Marcucci G., Calin G.A., Kornblau S.M., Kantarjian H., Bloomfield C.D., Andreeff M., Croce C.M. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
21. Blum W., Garzon R., Klisovic R.B., Schwind S., Walker A., Geyer S., Liu S., Havelange V., Becker H., Schaaf L., Mickle J., Devine H., Kefauver C., Devine S.M., Chan K.K., Heerema N.A., Bloomfield C.D., Grever M.R., Byrd J.C., Villalona-Calero M., Croce C.M., Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7473-7478.
22. Rangatia J., Bonnet D. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 2006, 20:68-76.
23. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
24. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.